This page contains brief information about fam-trastuzumab deruxtecan-nxki and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Fam-trastuzumab deruxtecan-nxki is approved to treat:
- Breast cancer that is HER2 positive and cannot be removed by surgery or has metastasized (spread to other parts of the body). It is used in adults who have already received at least two anti-HER2 treatments for metastatic disease.¹
- Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer) that is HER2 positive and is locally advanced or metastatic. It is used in adults who have received treatment that included trastuzumab.
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that fam-trastuzumab deruxtecan-nxki provides a clinical benefit in these patients.
Fam-trastuzumab deruxtecan-nxki is also being studied in the treatment of other types of cancer.
More About Fam-Trastuzumab Deruxtecan-nxki
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Fam-trastuzumab Deruxtecan-nxki - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Fam-trastuzumab Deruxtecan-nxki - Check for trials from NCI's list of cancer clinical trials now accepting patients.